I think he'd say something like this...

AL:

"For Type 2s, based on my understanding of the mechanism of the disease, AFREZZA may play an important role early in management of the disease. After all, the underlying deficit begins with the loss of prandial glucose control. As Peter noted, we intend to study this in finical trial not being planned. Early use of prandial insulins in Type 2 has not been pursued in the past, largely because of the deficiencies of current products. Yet many KOLs believe that there will an important role for earlier use of ultra-fast acting insulins that may even contribute to preventing progression of the disease."

http://seekingalpha.com/article/233332-mannkind-ceo-discusses-q3-2010-results-earnings-call-transcript?find=progression&all=false